Compare Datadog Inc (DDOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Recursion Pharmaceuticals Inc — how do they compare? Datadog Inc trades at $292.99 (market cap $98.31B), while Recursion Pharmaceuticals Inc trades at $4.32 (market cap $2.14B). The key difference: Datadog Inc is far larger — about 45.9× Recursion Pharmaceuticals Inc's market cap, and Datadog Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DDOG | RXRX | |
|---|---|---|
Market Cap | $98.31B | $2.14B |
Volume | 2,936,660 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $288.15 | $6.79 |
52-Week Low | $102.62 | $2.84 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $94.61B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $290.26, up 6.97% with strong bullish momentum approaching 52-week highs. The stock shows robust revenue growth reaching $3.43B in 2025, though profitability metrics remain mixed with a high P/E ratio of 547.6. Recent earnings beats and accelerating enterprise customer expansion support positive sentiment, while technical indicators show the stock trading near resistance at $288 with strong moving average support.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and AI-driven growth catalysts, though elevated valuation and negative cash flow trends present risks. The $276.10 consensus price target suggests limited upside from current levels, requiring continued execution on enterprise expansion and margin improvement to justify premium valuation.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
